Clinical Trial Update: Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation

View source ↗

Summary

This clinical trial update describes a target trial emulation comparing cefiderocol to best available therapy for infections caused by carbapenem-resistant Acin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carbapenem-resistant Acinetobacter Baumannii Infection

Drugs mentioned

• Cefiderocol (cefiderocol)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Carbapenem Resistant Bacterial Infection, Acinetobacter Baumannii Infection | Status: ACTIVE_NOT_RECRUITING